Using apolipoprotein B to manage dyslipidemia - Reply-I

Mayo Clinic Proceedings

Volumn 85, Issue 8, 2010, Pages 769-771

  Jacobson, Terry A ^a   Harper, Charles R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; LETTER; OUTCOME ASSESSMENT; RISK ASSESSMENT;

EID: 77955166153     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0378     Document Type: Letter

References (13)

1. Lavie C, Milani r, O'Keefe J. to B or not to B: is high density lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc. 2010;85(5):446-450.
2. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
3. McQueen MJ, Sniderman A; ACP Journal Club. Either cholesterol or apolipoprotein levels can be used to determine risk for CVd; triglycerides are not useful. Ann Intern Med. 2010;152(4):JC-212.
4. Gotto AM Jr, Whitney E, Stein EA, et al. relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/tex-CAPS). Circulation. 2000;101:477-484.
5. Simes RJ, Marschner IC, Hunt d, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with Pravastatin in Ischemic Disease (liPid) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105:1162-1169.
6. Holme I, Cater NB, Faergeman O, et al; Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (ideAl) Study Group. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease: insights from the Incremental Decrease In End-Points Through Aggressive Lipid-Lowering Trial (ideAl). Ann Med. 2008;40(6):456-464.
7. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/hdl, non-hdl cholesterol, or hs-CrP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from ProVe it-tiMi 22. Arterioscler Thromb Vasc Biol. 2009;29(3):424-430.
8. Kastelein JJP, van der Stieg W, Holme I, et al. Lipids, apoliproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117(23):3002-3009.
9. Ridker PM, Danielson E, Fonseca FA, et al; JUPiter Trial Study Group. Reduction in C-reactive protein and ldl cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPiter trial. Lancet. 2009;373(9670):1175-1182.
10. Sniderman A, Williams K, Cobbaert C. Apo B versus non-hdlC: what to do when they disagree. Curr Atheroscler Rep. 2009;11:358-363.
11. Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA; National Lipid Association Taskforce on Non-hdl Cholesterol. The importance of non-hdl cholesterol reporting in lipid management. J Clin Lipidol. 2008;2(4):267-273.
12. Hlatky MA, Greenland P, Arnett DK, et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408-2416.
13. de Graaf J, Couture P, Sniderman Ad. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Endocrinol Metab. 2008;4(11):608-618.